Tempest Therapeutics Inc. has announced details of its pipeline of in vivo CAR T product candidates differentiated by a CD7-targeted mRNA/LNP delivery approach, with application in the fields of oncology and immunology. Tempest’s in vivo CAR T platform, CD7-targeted mRNA lipid nanoparticle (CD7-tLNP), offers broader T-cell reach, enhanced delivery efficiency and scalable in vivo CAR T.